Elaprase
Named-patient access overview. Elaprase is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Elaprase (idursulfase) is a recombinant form of human iduronate-2-sulfatase, the lysosomal enzyme that is deficient in Hunter syndrome (mucopolysaccharidosis type II, MPS II), an X-linked lysosomal storage disorder that affects primarily males. The US Food and Drug Administration approved Elaprase in July 2006 for the treatment of patients with Hunter syndrome to improve walking capacity. Elaprase is approximately manufactured and marketed globally by Takeda, which acquired the original developer Shire in 2019. The therapy is delivered as a weekly intravenous infusion at a typical dose of 0.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Elaprase
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Elaprase is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Elaprase in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Elaprase
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.